Corona Remedies Limited has released its investor presentation for the second quarter and half-year ended September 30, 2026. The presentation details the company’s financial and operational performance, including key highlights such as revenue growth, EBITDA, and Profit After Tax. It also outlines strategic initiatives, market performance, and future growth strategies.
Corona Remedies Limited Releases Investor Presentation for Q2 & H1 FY27
Corona Remedies Limited has officially submitted its investor presentation to the stock exchanges, detailing the company’s financial and operational performance for the second quarter (Q2 FY27) and the first half of the fiscal year (H1 FY27), ending September 30, 2026.
Key Financial and Operational Highlights
The presentation highlights significant achievements, including:
- Revenue: INR 441.2 Cr for Q2 FY27 (up 22.2% YoY) and INR 863.6 Cr for H1 FY27 (up 22.0% YoY).
- EBITDA: INR 96.0 Cr for Q2 FY27 (up 22.3% YoY) and INR 189.1 Cr for H1 FY27 (up 27.5% YoY). The EBITDA margin stood at 21.7% for Q2 FY27 and 21.9% for H1 FY27.
- PAT: INR 60.3 Cr for Q2 FY27 (up 15.3% YoY) and INR 120.4 Cr for H1 FY27 (up 22.2% YoY). The PAT margin was 13.7% for Q2 FY27 and 13.9% for H1 FY27.
Market Performance and Strategic Initiatives
Corona Remedies reported that its India business contributed 97.1% of the total revenue in H1 FY27. Chronic and sub-chronic therapies accounted for approximately 72.1% of the revenue in H1 FY27. The company also noted an improvement in its market rank, moving to 26th from 27th in MAT Sep-26 in IPM (Indian Pharmaceutical Market). Notable achievements include the renewal of EU-GMP certification for the Oral Solid Dosage line, the inauguration of a Hormone Facility with EU-GMP certification, and receiving ANVISA GMP (Brazil) Certification.
Future Outlook and Growth Strategies
The presentation outlines the company’s future growth strategies, focusing on increasing market share within the domestic IPM, expanding into other therapeutic areas, product portfolio management, strategic acquisitions and in-licensing agreements, and expanding sales in select overseas markets. The company emphasizes its strong manufacturing capabilities and commitment to quality, with multiple facilities certified by international regulatory bodies such as EU-GMP, EAEU-GMP, and ANVISA-GMP.
Source: BSE
